Frost & Sullivan releases 'Research Report on the Chinese Biosimilar Market (Part 2)'

Based on research into the Chinese biosimilar market, Frost & Sullivan (Frost & Sullivan) has released a relevant industry report. The report points out that due to differences in industrial structure, the best-selling drugs in China's pharmaceutical market are very different from those in the global market. Among the top 10 best-selling drugs in China in 2018, only 2 were biologics (insulin), while the other 8 were chemical drugs. In the future, the structure of best-selling drugs in China will develop towards a global trend, with more biologics becoming leading blockbuster products in terms of sales. This report is part three of the series, for more content please refer to 'Research on the Chinese Biosimilar Market (Part One) (Part Two)'.